John D. England
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
John D. England has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Gary M. Franklin
2 shared publications- Rima El-Abassi
Louisiana State University Health Sciences Center
2 shared publications - Brian J. Copeland
Louisiana State University Health Sciences Center – New Orleans, Department of Neurology, 1542 Tulane Ave, Rm 763, New Orleans, LA 70112, United States of America
1 shared publication - Cornel T. Rogers
Epilepsy Center of Excellence, Louisiana State University Health Sciences Center, New Orleans, LA, USA
1 shared publication - Daniel L. Raines
Louisiana State University Health Sciences Center
1 shared publication - David J. Houghton
Ochsner Foundation Hospital, United States of America
1 shared publication
Latest Publications
- 17 March 2022
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 436
Book Review
- 1 August 2021
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 427, 117551
Characterization of adult patients with Guillain–Barré syndrome during the arboviral infection outbreaks in Honduras
- 1 August 2021
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 427, 117551
Characterization of adult patients with Guillain–Barré syndrome during the arboviral infection outbreaks in Honduras
- Open Access
- 1 February 2019
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 397, 84-91
Current practice patterns in CIDP: A cross-sectional survey of neurologists in the United States
- 1 February 2019
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 397, 84-91
Open AccessCurrent practice patterns in CIDP: A cross-sectional survey of neurologists in the United States
- 1 June 2017
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 377, 197-206
Whipple's disease
- 1 June 2017
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 377, 197-206
Whipple's disease
- 13 September 2014
- Published by Wiley in Muscle & Nerve
- Vol. 50 (5) , 721-722
Making sense of the muscular dystrophies: Diagnosis and treatment guideline for limb-girdle muscular dystrophy
- 13 September 2014
- Published by Wiley in Muscle & Nerve
- Vol. 50 (5) , 721-722
Making sense of the muscular dystrophies: Diagnosis and treatment guideline for limb-girdle muscular dystrophy
- 1 September 2014
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 344 (1-2) , 5-19
Fabry's disease
- 1 September 2014
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 344 (1-2) , 5-19
Fabry's disease
- Open Access
- 13 August 2014
- Published by MDPI AG in Neurology International
- Vol. 6 (3) , 53-55
Unihemispheric Burst Suppression
Burst suppression (BS) consists of bursts of high-voltage slow and sharp wave activity alternating with periods of background suppression in the electroencephalogram (EEG). When induced by deep anesthesia or encephalopathy, BS is bihemispheric and is often viewed as a non-epileptic phenomenon. In contrast, unihemispheric BS is rare and its clinical significance is poorly understood. We describe here two cases of unihemispheric BS. The first patient is a 56-year-old woman with a left temporoparietal tumor who presented in convulsive status epilepticus. EEG showed left hemispheric BS after clinical seizure termination with lorazepam and propofol. The second patient is a 39-year-old woman with multiple medical problems and a vague history of seizures. After abdominal surgery, she experienced a convulsive seizure prompting treatment with propofol. Her EEG also showed left hemispheric BS. In both cases, increasing the propofol infusion rate resulted in disappearance of unihemispheric BS and clinical improvement. The prevailing view that typical bihemispheric BS is non-epileptic should not be extrapolated automatically to unihemispheric BS. The fact that unihemispheric BS was associated with clinical seizure and resolved with propofol suggests that, in both cases, an epileptic mechanism was responsible for unihemispheric BS.
- 13 August 2014
- Published by MDPI AG in Neurology International
- Vol. 6 (3) , 53-55
Open AccessUnihemispheric Burst Suppression
Burst suppression (BS) consists of bursts of high-voltage slow and sharp wave activity alternating with periods of background suppression in the electroencephalogram (EEG). When induced by deep anesthesia or encephalopathy, BS is bihemispheric and is often viewed as a non-epileptic phenomenon. In contrast, unihemispheric BS is rare and its clinical significance is poorly understood. We describe here two cases of unihemispheric BS. The first patient is a 56-year-old woman with a left temporoparietal tumor who presented in convulsive status epilepticus. EEG showed left hemispheric BS after clinical seizure termination with lorazepam and propofol. The second patient is a 39-year-old woman with multiple medical problems and a vague history of seizures. After abdominal surgery, she experienced a convulsive seizure prompting treatment with propofol. Her EEG also showed left hemispheric BS. In both cases, increasing the propofol infusion rate resulted in disappearance of unihemispheric BS and clinical improvement. The prevailing view that typical bihemispheric BS is non-epileptic should not be extrapolated automatically to unihemispheric BS. The fact that unihemispheric BS was associated with clinical seizure and resolved with propofol suggests that, in both cases, an epileptic mechanism was responsible for unihemispheric BS.
- Open Access
- 18 July 2013
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 10 (1) , 865-88
The Lyme disease spirochete Borrelia burgdorferi induces inflammation and apoptosis in cells from dorsal root ganglia
Background: Lyme neuroborreliosis (LNB), caused by the spirocheteBorrelia burgdorferi, affects both the peripheral and the central nervous systems. Radiculitis or nerve root inflammation, which can cause pain, sensory loss, and weakness, is the most common manifestation of peripheral LNB in humans. We previously reported that rhesus monkeys infected withB.burgdorferidevelop radiculitis as well as inflammation in the dorsal root ganglia (DRG), with elevated levels of neuronal and satellite glial cell apoptosis in the DRG. We hypothesized thatB.burgdorferiinduces inflammatory mediators in glial and neuronal cells and that this inflammatory milieu precipitates glial and neuronal apoptosis.Methods: To model peripheral neuropathy in LNB we incubated normal rhesus DRG tissue explants with liveB.burgdorferi ex vivoand identified immune mediators, producer cells, and verified the presence ofB.burgdorferiin tissue sections by immunofluorescence staining and confocal microscopy. We also set up primary cultures of DRG cells from normal adult rhesus macaques and incubated the cultures with liveB.burgdorferi. Culture supernatants were subjected to multiplex ELISA to detect immune mediators, while the cells were evaluated for apoptosis by thein situTUNEL assay. A role for inflammation in mediating apoptosis was assessed by evaluating the above phenomena in the presence and absence of various concentrations of the anti-inflammatory drug dexamethasone. As Schwann cells ensheath the dorsal roots of the DRG, we evaluated the potential of liveB.burgdorferito induce inflammatory mediators in human Schwann cell (HSC) cultures.Results: Rhesus DRG tissue explants exposed to liveB.burgdorferishowed localization of CCL2 and IL-6 in sensory neurons, satellite glial cells and Schwann cells while IL-8 was seen in satellite glial cells and Schwann cells. LiveB.burgdorferiinduced elevated levels of IL-6, IL-8 and CCL2 in HSC and DRG cultures and apoptosis of sensory neurons. Dexamethasone reduced the levels of immune mediators and neuronal apoptosis in a dose dependent manner.Conclusion: In this model,B.burgdorferiinduced an inflammatory response and neuronal apoptosis of DRG. These pathophysiological processes could contribute to peripheral neuropathy in LNB.
- 18 July 2013
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 10 (1) , 865-88
Open AccessThe Lyme disease spirochete Borrelia burgdorferi induces inflammation and apoptosis in cells from dorsal root ganglia
Background: Lyme neuroborreliosis (LNB), caused by the spirocheteBorrelia burgdorferi, affects both the peripheral and the central nervous systems. Radiculitis or nerve root inflammation, which can cause pain, sensory loss, and weakness, is the most common manifestation of peripheral LNB in humans. We previously reported that rhesus monkeys infected withB.burgdorferidevelop radiculitis as well as inflammation in the dorsal root ganglia (DRG), with elevated levels of neuronal and satellite glial cell apoptosis in the DRG. We hypothesized thatB.burgdorferiinduces inflammatory mediators in glial and neuronal cells and that this inflammatory milieu precipitates glial and neuronal apoptosis.Methods: To model peripheral neuropathy in LNB we incubated normal rhesus DRG tissue explants with liveB.burgdorferi ex vivoand identified immune mediators, producer cells, and verified the presence ofB.burgdorferiin tissue sections by immunofluorescence staining and confocal microscopy. We also set up primary cultures of DRG cells from normal adult rhesus macaques and incubated the cultures with liveB.burgdorferi. Culture supernatants were subjected to multiplex ELISA to detect immune mediators, while the cells were evaluated for apoptosis by thein situTUNEL assay. A role for inflammation in mediating apoptosis was assessed by evaluating the above phenomena in the presence and absence of various concentrations of the anti-inflammatory drug dexamethasone. As Schwann cells ensheath the dorsal roots of the DRG, we evaluated the potential of liveB.burgdorferito induce inflammatory mediators in human Schwann cell (HSC) cultures.Results: Rhesus DRG tissue explants exposed to liveB.burgdorferishowed localization of CCL2 and IL-6 in sensory neurons, satellite glial cells and Schwann cells while IL-8 was seen in satellite glial cells and Schwann cells. LiveB.burgdorferiinduced elevated levels of IL-6, IL-8 and CCL2 in HSC and DRG cultures and apoptosis of sensory neurons. Dexamethasone reduced the levels of immune mediators and neuronal apoptosis in a dose dependent manner.Conclusion: In this model,B.burgdorferiinduced an inflammatory response and neuronal apoptosis of DRG. These pathophysiological processes could contribute to peripheral neuropathy in LNB.
- 1 February 2012
- Published by Wolters Kluwer Health in Continuum
- Vol. 18 (1) , 181-184
Difficult Decisions
The decision to use opioids to treat chronic neuropathic pain is complex and somewhat controversial. Although opioid therapy may be appropriate for some patients with chronic neuropathic pain, physicians must implement strategies to reduce opioid abuse, addiction, and diversion. The decision to use chronic opioids should be made proactively with institution of best practices to ensure safe and effective use. As with all aspects of chronic pain management, better education of both health care providers and patients is necessary. Fortunately, specific recommendations for the safe and effective use of opioids are now available in several recently published guidelines. The best practices embodied in these guidelines should be considered for widespread adoption by both individual providers and health care systems.
- 1 February 2012
- Published by Wolters Kluwer Health in Continuum
- Vol. 18 (1) , 181-184
Difficult Decisions
The decision to use opioids to treat chronic neuropathic pain is complex and somewhat controversial. Although opioid therapy may be appropriate for some patients with chronic neuropathic pain, physicians must implement strategies to reduce opioid abuse, addiction, and diversion. The decision to use chronic opioids should be made proactively with institution of best practices to ensure safe and effective use. As with all aspects of chronic pain management, better education of both health care providers and patients is necessary. Fortunately, specific recommendations for the safe and effective use of opioids are now available in several recently published guidelines. The best practices embodied in these guidelines should be considered for widespread adoption by both individual providers and health care systems.